Habit-forming effect. Should not be taken if there is any possibility of waking up temporarily in the middle of sleep to engage in activities (eg, work). Avoid use at the same time or right after meals since sleep induction may be delayed. Patients w/ organic brain disorders; moderate & severe resp function disorders. Consider the necessity of continuing use when symptoms improve & ensure that Dayvigo is not aimlessly administered. May impair daytime wakefulness. CNS depressant effects may persist for up to several days after discontinuation in some patients. Potential for next-day somnolence. Co-administration w/ other CNS depressants eg, benzodiazepines, opioids, TCAs. Not recommended to use w/ other drugs to treat insomnia. Avoid alcohol consumption. Sleep paralysis, hypnagogic/hypnopompic hallucinations, & cataplexy-like symptoms can occur. Discontinue immediately if patient experiences a complex sleep behavior (eg, sleep-walking, sleep-driving & engaging in other activities while not fully awake). Consider effect on resp function if prescribed to patients w/ compromised resp function; moderate to severe obstructive sleep apnea or COPD. Worsening of depression & suicidal thoughts & actions (including completed suicides) in primarily depressed patients treated w/ hypnotics; lowest feasible number of tab should be prescribed at any one time to prevent intentional overdose. Initiate treatment of insomnia only after careful patient evaluation for medical &/or psychiatric disorder. May induce drowsiness, impairment of attention, conc & reflex movements; avoid potentially hazardous activities (eg, operating machinery or driving a motor vehicle). Mild & moderate hepatic impairment. Severe renal impairment. Pregnant or possibly pregnant women. Avoid use in lactating women; stop breastfeeding when there is no other choice but to administer the drug. Ped patients. Elderly.
Sign Out
